TherapeuticsMD (TXMD) Misses Q3 EPS by $1.09

TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($3.13), $1.09 worse than the analyst estimate of ($2.04). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $30.2 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
• Goldman's Garrett sees investors dialing back tech exposure into H2
• Kraken Robotics closes $615M Covelya acquisition, raises 2026 outlook